2349393-21-9
2349393-21-9
Chemical Structure
KRAS G12C inhibitor 15
- CAS No.: 2349393-21-9
- Formula:C25H21ClF2N4O3
- Molecular Weight:498.91
IUPAC Name: (2R,4aR,10S)-3-acryloyl-11-chloro-9-fluoro-10-(2-fluoro-6-hydroxyphenyl)-2,6-dimethyl-2,3,4,4a-tetrahydro-1H-pyrazino[1',2':4,5]pyrazino[2,3-c]quinolin-5(6H)-one
InChIKey: XDVMVEOFPVCHEL-SJKOYZFVSA-N
SMILES: FC1=C(N=CC(N2C)=C3N4[C@H](CN(C(C=C)=O)[C@H](C)C4)C2=O)C3=CC(Cl)=[C@@]1[C@@]5=C(F)C=CC=C5O
Biological Activity: KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 22, has an IC50 of 5 nM[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KRAS G12C inhibitor 15 | 98.47% | KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 22, has an IC50 of 5 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
KRAS G12C inhibitor 14 | 99.00% | KRas G12C inhibitor 14 (Compound 17) is a potent KRAS G12C inhibitor (IC50 = 18 nM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
KRAS G12C inhibitor 16 | KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 39, has an IC50 of 97 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
KRAS G12C inhibitor 17 | KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 82, has an IC50 of 5 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
KRAS inhibitor-7 | KRAS inhibitor-7 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound B. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
KRAS G12C inhibitor 53 | KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ARS-2102 | ARS-2102 is a potent covalent KRAS G12C inhibitor for use in cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fulzerasib | 99.60% | Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905).. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sosimerasib | 98.63% | Sosimerasib is an orally active KRASG12C inhibitor. Sosimerasib can be used in research related to non-small cell lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ARS-1323 | 99.67% | ARS-1323 is a KRAS G12C inhibitor. ARS-1323 specifically binds to the cysteine residue on the mutant K-Ras protein, locks it in the GDP-bound conformation, thereby blocking K-Ras activation and downstream signaling pathways. ARS-1323 can be used to investigate the signal transduction mechanisms and growth characteristics of tumor cells driven by K-Ras G12C. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ARS-1620 | 99.59% | ARS-1620 is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
